Clinical Research Hospitals Immune Response Trials 
Drug Discovery World
MAY 30, 2024
Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. RA: Could you tell us about the LEGACY03 trial? It is these differences in immune response, which have stimulated our research to improve vaccine design.
Drug Discovery World
APRIL 14, 2023
She is also a Professor of Pathology at the Johns Hopkins University School of Medicine, Co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care, and Deputy Director of the Johns Hopkins Institute for Clinical and Translational Research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NIH Director's Blog: Drug Development
FEBRUARY 16, 2021
hospitals are stretched to the limit trying to help people battling serious cases of COVID-19. Cutting through the usual red tape and working with an intense sense of purpose, the partnership took a mere matter of weeks to set up its first four clinical trials. Credit: NIH Right now, many U.S.
Drug Target Review
FEBRUARY 21, 2024
Stem cell transplants primarily help the immune response through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.” In addition to this alliance, we also conduct our own research and participate in clinical trials to bring the benefits of medical research to the community level.
The Pharma Data
JANUARY 17, 2021
The NDA was built on data from the Phase III VICTORIA trial. The primary endpoint of the study was composite of time to first occurrence of heart failure hospitalization or cardiovascular death. The NDA was supported by results from two pivotal trials, Phase III AURORA and Phase II AURA-LV.
The Pharma Data
NOVEMBER 1, 2020
Trial facilitated with coll a boration of Harvard Medical School and one of the world’s top Neurologist, Dr. Howard Weiner. Clinical Data Expected by End of Year. The clinical data from this trial is expected to available by the end of this year. Brazil has reported almost 5.5M
The Pharma Data
NOVEMBER 10, 2020
This clinical study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of Foralumab. The trial is a dose-ranging, open-label study that will enroll 60 patients in the U.S. NEW YORK and LONDON, Nov. NEW YORK and LONDON, Nov. and Europe. Dr. Howard L.
Expert insights. Personalized for you.
147 
Let's personalize your content